BIOTECHNOLOGY VALUE FUND L P

CIK 0000918923

8 SPACs with a current declared position, filed between Mar 5, 2021 and Aug 12, 2026. 3 of them were re-affirmed in the last 12 months. The rest are the filer’s last word on a position, not proof it is still held: an amendment is only required on a material change, so a fund that sells below 5% may never file again.

SPACs declared

every position whose latest statement stands — the record

Re-affirmed in 12 months

filed inside 365 days — what a reader means by "owns"

Still live

positions in SPACs still searching or in an announced deal

Median stake

6.1%

6.4% across the re-affirmed positions · max 31.4%

6 passive (13G)2 activist (13D)103 superseded statements on file

Positions

one row per SPAC — every figure read from the accession in the Source column

8 of 8 shown · 5 positions have not been amended in over a year

	SPAC			Voting	Dispositive			Source
HLXA	Helix Acquisition Corp11 reporting persons on this schedule	31.4%	19,751,284	11,297 / 19,751,284	11,297 / 19,751,284	Closed (deSPAC)	Oct 8, 2024Stale	SC 13D/A · may seek to influence control0000921895-24-002262 33 earlier statements
BCYP	Big Cypress Acquisition Corp.10 reporting persons on this schedule	10.0%	9,178,282	0 / 9,178,282	0 / 9,178,282	Closed (deSPAC)	Dec 4, 2023Stale	SC 13G0000921895-23-002708
RACC	Research Alliance Corp III	6.4%	500,000	not stated	not stated	Deal announced	May 29, 2026Fresh	SC 13G0000921895-26-001505
RACD	Research Alliance Corp IV	6.4%	500,000	not stated	not stated	Searching	Jul 20, 2026Fresh	SC 13G0000921895-26-001836
FVAM	5:01 Acquisition Corp.10 reporting persons on this schedule	5.8%	500,000	0 / 500,000	0 / 500,000	Liquidated	Mar 5, 2021Stale	SC 13G0000921895-21-000645
TCGX	TCGX Acquisition	5.5%	500,000	not stated	not stated	Searching	Aug 12, 2026Fresh	SC 13G0000921895-26-002072
AMHC	Amplitude Healthcare Acquisition Corp10 reporting persons on this schedule	0.0%	0	0 / 0	0 / 0	Closed (deSPAC)	Feb 14, 2024Stale	SC 13G/A0000921895-24-000442 10 earlier statements
RACA	Therapeutics Acquisition Corp.10 reporting persons on this schedule	0.0%	0	0 / 0	0 / 0	Closed (deSPAC)	Dec 20, 2023Stale	SC 13D/A · may seek to influence control0000921895-23-002787 60 earlier statements

103 superseded statements (newest 11 shown)

An amendment replaces a stake as current; it never erases the record of it. These are the earlier statements, each with the accession that replaced it — kept because “what did this filer say in 2022” is a different question from “what does it say now”, and only the second one has an answer above.

HLXA Helix Acquisition Corp2.0% · SC 13D/A Oct 8, 2024replaced Jun 30, 2023 by 0001193805-23-000934
HLXA Helix Acquisition Corp34.6% · SC 13D/A Mar 5, 2024replaced Oct 8, 2024 by 0000921895-24-002262
RACA Therapeutics Acquisition Corp.16.5% · SC 13D Nov 6, 2023replaced Dec 20, 2023 by 0000921895-23-002787
HLXA Helix Acquisition Corp35.8% · SC 13D/A Jun 30, 2023replaced Mar 5, 2024 by 0000921895-24-000582
RACA Therapeutics Acquisition Corp.8.7% · SC 13G/A Feb 14, 2023replaced Nov 6, 2023 by 0000921895-23-002462
AMHC Amplitude Healthcare Acquisition Corp9.1% · SC 13G Feb 6, 2023replaced Feb 14, 2024 by 0000921895-24-000442
RACA Therapeutics Acquisition Corp.5.4% · SC 13G Sep 26, 2022replaced Feb 14, 2023 by 0000921895-23-000536
HLXA Helix Acquisition Corp58.9% · SC 13D Apr 18, 2022replaced Jun 30, 2023 by 0001193805-23-000934
RACA Therapeutics Acquisition Corp.3.2% · SC 13G/A Feb 14, 2022replaced Sep 26, 2022 by 0000921895-22-002703
RACA Therapeutics Acquisition Corp.6.8% · SC 13G/A Feb 16, 2021replaced Feb 14, 2022 by 0000921895-22-000449
RACA Therapeutics Acquisition Corp.5.9% · SC 13G Jul 20, 2020replaced Feb 16, 2021 by 0000921895-21-000404

Reporting persons on this filer's schedules

one filer, several names — collapsed once, shown in full

A joint Schedule 13 names every person who beneficially owns the shares — the management company, the funds it advises, the general partner and often the individual who controls all three. They report the same shares. Counting them separately would publish this filer’s footprint two or three times over, so they are counted once, under CIK 0000918923. This filer has named 17 of them across the schedules in the table above:

BVF GP Holdings
BVF I GP
BVF II GP
BVF INC
BVF Inc
BVF Partners
BVF Partners OS
Biotechnology Value Fund
Biotechnology Value Fund II
Biotechnology Value Fund Ii
Biotechnology Value Trading Fund OS
Bvf Gp Holdings
Bvf Partners
Bvf Partners L P/Il
Bvf Partners Os
Mark N. Lampert
Spike Loy

Appears alongside

other filers with a current declared position in the same SPACs

Co-occurrence in the disclosure record, and nothing more. It is not evidence of a group, an agreement or acting in concert — filers who act as a group say so on the cover page and file a 13D. Two arbitrage funds above 5% in the same shell is the ordinary shape of this market. The second number restricts both sides to statements filed in the last 12 months, because a 2021 stake beside a 2026 one is two facts about two different years.

Every percentage above is the one printed on the cover page of the filing cited beside it — a percentage of the shares outstanding on that date. A SPAC’s float collapses at each redemption, so two of these percentages are percentages of two different companies and they do not add. Rows are one per SPAC: where a joint schedule names several reporting persons, the largest single figure is shown rather than their sum, because a manager and the funds it advises beneficially own the same shares. Nothing on this page is derived from a 13F, a vendor holdings file or a press release. See how this is built.